Gluttony for Simplicity: Medicare's Costly Catch Medicare's pilot program to make GLP 1 diabetes medications more affordable has raised questions about who qualifies.
The $50 a month price tag sounds attractive, but it comes with a catch: patients with the most serious illnesses may be denied treatment due to "medical necessity.
" The formula used to determine eligibility weighs medical history against financial feasibility, prioritizing those who can afford to pay more because they have fewer health complications.